GlassScriptPhysician profile
Kearston Taylor
NPI 1285368357
$5,047.01
in general payments reported to CMS, 2019-2025
29 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $528 · 2023: $1,304 · 2024: $1,877 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,466 · Education: $53.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,465.55 |
| Education | $53.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,017.65 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $936.54 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $676.69 | 2023-2025 | Dupixent |
| Genzyme Corporation | $583.00 | 2023-2025 | |
| Grifols USA, LLC | $330.50 | 2022-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $226.11 | 2023-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.30 | 2022-2025 | Ofev, Spiriva Respimat |
| Amgen INC. | $97.55 | 2023-2024 | Tavneos, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $92.67 | 2022-2025 | Glassia |
| Inspire Medical Systems, INC. | $90.10 | 2025 | Inspire |
| Lilly USA, LLC | $89.98 | 2025 | Zepbound |
| Insmed, INC. | $89.97 | 2024-2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $82.20 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $76.47 | 2022-2024 | Opsumit, Uptravi |
| Philips North America LLC | $70.53 | 2022-2025 | Vest Therapy Und |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $57.06 | 2025 | Acthar |
| Harmony Biosciences LLC | $50.77 | 2022-2025 | |
| Pfizer INC. | $47.77 | 2023-2024 | |
| Mylan Specialty L.P. | $47.30 | 2024 | Yupelri |
| Baxter Healthcare | $34.89 | 2024 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $34.81 | 2024 | Tyvaso |
| Shionogi INC | $28.62 | 2022 | |
| Jazz Pharmaceuticals INC. | $28.32 | 2024 | |
| Genentech USA, INC. | $20.50 | 2023 | Xolair |
| Verona Pharma, INC. | $18.67 | 2025 | Ohtuvayre |
| Melinta Therapeutics, LLC | $18.19 | 2024 | Vabomere, Rezzayo |
| Inogen, INC. | $16.70 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.30 | 2023 | |
| Kaleo, INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kearston Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.